Stocks: Cowen and Company Reaffirms Buy Rating for Syndax Pharmaceuticals Inc (SNDX)

Stocks: Cowen and Company Reaffirms Buy Rating for Syndax Pharmaceuticals Inc (SNDX)

Cowen and Company reaffirmed their buy rating on shares of Syndax Pharmaceuticals Inc (NASDAQ:SNDX) in a report released on Tuesday.

“Continued solid progress with ENCORE 601, which combines Entinostat with Keytruda,.”,” the firm’s analyst commented.

Other equities research analysts also recently issued research reports about the company. Oppenheimer Holdings Inc. set a $25.00 price target on Syndax Pharmaceuticals and gave the stock a buy rating in a research report on Saturday, March 4th. Instinet initiated coverage on Syndax Pharmaceuticals in a research report on Wednesday, March 1st. They set a buy rating and a $27.00 price target on the stock. Nomura initiated coverage on Syndax Pharmaceuticals in a research report on Wednesday, March 1st. They set a buy rating on the stock. Finally, FBR & Co initiated coverage on Syndax Pharmaceuticals in a research report on Thursday, March 16th. They set an outperform rating and a $27.00 price target on the stock. Nine equities research analysts have rated the stock with a buy rating, Syndax Pharmaceuticals has a consensus rating of Buy and a consensus target price of $23.71.

Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) opened at 8.61 on Tuesday. Syndax Pharmaceuticals has a one year low of $6.31 and a one year high of $18.03. The firm’s market cap is $156.97 million. The stock’s 50 day moving average price is $11.06 and its 200 day moving average price is $10.14.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Monday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.03. The business had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.31 million. Syndax Pharmaceuticals had a negative return on equity of 306.05% and a negative net margin of 3,388.98%. On average, equities analysts anticipate that Syndax Pharmaceuticals will post ($3.62) earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of SNDX. C WorldWide Group Holding A S acquired a new stake in shares of Syndax Pharmaceuticals during the first quarter worth $163,000. Laurion Capital Management LP acquired a new stake in shares of Syndax Pharmaceuticals during the third quarter worth $305,000. Trexquant Investment LP acquired a new stake in shares of Syndax Pharmaceuticals during the first quarter worth $283,000. TIAA CREF Investment Management LLC increased its stake in shares of Syndax Pharmaceuticals by 36.2% in the first quarter. TIAA CREF Investment Management LLC now owns 22,924 shares of the company’s stock worth $315,000 after buying an additional 6,091 shares in the last quarter. Finally, Elkfork Partners LLC acquired a new stake in shares of Syndax Pharmaceuticals during the fourth quarter worth $204,000. 62.22% of the stock is currently owned by hedge funds and other institutional investors.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Related posts

Leave a Comment